Moriyasu Anai
Overview
Explore the profile of Moriyasu Anai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anai M, Inoue H, Saruwatari K, Oda S, Shiraishi S, Akaike K, et al.
Respir Investig
. 2024 Sep;
62(6):1072-1078.
PMID: 39316922
Background: Fluorine- 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (F-FDG PET/CT) is routinely used to stage non-small cell lung cancer (NSCLC). However, whether F-FDG accumulation in primary tumors affects the efficacy of...
2.
Anai M, Hamada S, Jodai T, Okabayashi H, Saruwatari K, Tomita Y, et al.
Intern Med
. 2024 May;
64(2):267-271.
PMID: 38811224
Pulmonary tumor embolisms (PTEs) are primarily caused by adenocarcinoma. However, only a few cases of oropharyngeal carcinoma have been reported. We herein report a 47-year-old man who presented with a...
3.
Anai M, Saruwatari K, Imamura K, Fujino K, Jodai T, Sakata S, et al.
J Thorac Dis
. 2024 Mar;
16(2):1151-1160.
PMID: 38505064
Background: The clinical impact of tumor microvessels on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in mutation-positive non-small cell lung cancer (NSCLC) is unclear. Thus, the aim...
4.
Tomita Y, Sakata S, Imamura K, Iyama S, Jodai T, Saruwatari K, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201474
The gut microbiota has emerged as a key regulator of immune checkpoint inhibitor (ICI) efficacy. Therapeutic approaches aimed at manipulating the microbiota through targeted reconstitution to enhance cancer treatment outcomes...
5.
Anai M, Yoshida C, Izumi H, Muramoto K, Saruwatari K, Tomita Y, et al.
Respirol Case Rep
. 2022 Dec;
11(1):e01074.
PMID: 36540290
A 29-year-old man presented to our hospital with severe eosinophilic asthma. He needed a short OCS burst for exacerbation of asthma once every 1 or 2 months, although he used...
6.
Jodai Y, Hamada S, Yamada M, Masuda Y, Anai M, Jodai T, et al.
Thorac Cancer
. 2022 Dec;
14(3):331-335.
PMID: 36484334
Sebaceous carcinoma is a rare cutaneous malignant tumor, usually occurring on the eyelids, head, neck, and trunk. There have been few reports about sebaceous carcinoma with primary lung cancer, for...
7.
Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, et al.
Oncoimmunology
. 2022 Jun;
11(1):2081010.
PMID: 35655708
Oral microbiota is associated with human diseases including cancer. Emerging evidence suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into the gut, negatively influence the...
8.
Anai M, Saruwatari K, Ikeda T, Oda S, Tajima Y, Jodai T, et al.
Int J Clin Oncol
. 2022 Feb;
27(5):863-870.
PMID: 35192084
Background: Lung cancer patients have a high risk of cerebral infarction, but the clinical significance of cerebral infarction in advanced non-small cell lung cancer (NSCLC) remains unclear. This study aimed...
9.
Anai M, Yoshida C, Ozono K, Furukawa H, Ishimaru Y, Sakata S, et al.
Allergol Int
. 2022 Jan;
71(2):259-261.
PMID: 35074267
No abstract available.
10.
Anai M, Akaike K, Iwagoe H, Akasaka T, Higuchi T, Miyazaki A, et al.
Respir Investig
. 2020 Dec;
59(2):187-193.
PMID: 33281114
Background: In December 2019, the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan, China, and has since spread throughout the world. This study...